Wells Fargo & Company Biomea Fusion, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 8,515 shares of BMEA stock, worth $34,741. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,515
Previous 8,849
3.77%
Holding current value
$34,741
Previous $39,000
120.51%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BMEA
# of Institutions
104Shares Held
17.8MCall Options Held
1.68MPut Options Held
410K-
Cormorant Asset Management, LP Boston, MA3.57MShares$14.6 Million2.53% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$9.57 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$8.6 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$5.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.38MShares$5.62 Million0.01% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $120M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...